Related references
Note: Only part of the references are listed.A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral gamma-Secretase Inhibitor PF-03084014
Wells A. Messersmith et al.
CLINICAL CANCER RESEARCH (2015)
Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models
Cathy C. Zhang et al.
CLINICAL CANCER RESEARCH (2012)
Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia
Jeremy B. Samon et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia
Maddalena Paganin et al.
BLOOD REVIEWS (2011)
Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies
Jon C. Aster et al.
JOURNAL OF PATHOLOGY (2011)
Evaluation of Selective gamma-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design
Ping Wei et al.
MOLECULAR CANCER THERAPEUTICS (2010)
NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity
Florence Armstrong et al.
BLOOD (2009)
Acute lymphoblastic leukaemia
Ching-Hon Pui et al.
LANCET (2008)
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia
Teresa Palomero et al.
NATURE MEDICINE (2007)
Notch signaling, gamma-secretase inhibitors, and cancer therapy
Ie-Ming Shih et al.
CANCER RESEARCH (2007)
CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to γ-secretase inhibitors
T. Palomero et al.
LEUKEMIA (2006)
T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling
WS Pear et al.
CURRENT OPINION IN HEMATOLOGY (2004)
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia
AA Ferrando et al.
CANCER CELL (2002)
Share Paper
